デフォルト表紙
市場調査レポート
商品コード
1541407

気管支拡張薬市場レポート:適応症別、薬剤タイプ別、投与経路別、地域別、2024~2032年

Bronchodilators Market Report by Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Others), Drug Type, Route of Administration, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.05円
気管支拡張薬市場レポート:適応症別、薬剤タイプ別、投与経路別、地域別、2024~2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の気管支拡大薬市場規模は2023年に376億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに559億米ドルに達し、2024~2032年の間に4.4%の成長率(CAGR)を示すと予測しています。

気管支拡大薬は、喘息、肺気腫、慢性閉塞性肺疾患(COPD)など、気道が狭く炎症を起こしている長期的な状態にある患者の治療に用いられる薬剤です。気道や気管支の周りの筋肉を弛緩させ、肺の粘液を取り除き、呼吸を楽にすることで、関連する症状を緩和します。錠剤、液剤、ネブライザー、定量吸入器、粉末吸入器などの形態で販売されています。現在では、気管支拡大薬は吸入コルチコステロイドの効果を高めるためにも利用されており、喘息の炎症を抑え、再燃を防ぐための主要な治療として作用しています。

気管支拡大薬市場傾向

コロナウイルス感染症(COVID-19)による急性呼吸器感染症患者数の大幅な増加は、世界中で気管支拡大薬の必要性に影響を与えている主要要因の一つです。これとは別に、大気汚染レベルの増加、喫煙者数の増加、世界の感染症の蔓延が、肺疾患の発症リスクを高めています。これは市場のもう一つの成長促進要因として作用しています。加えて、肺機能は加齢とともに徐々に低下し、呼吸がわずかに困難になります。このことは、高齢者人口の増加や個人消費能力の大幅な上昇とともに、市場を牽引しています。医療インフラや診断方法の改善、非侵襲的処置へのシフトの高まりといったその他の要因も、市場の成長を後押ししています。さらに、既存製品の限界を克服するのに役立ついくつかの新しいクラスの気管支拡大剤が前臨床段階にあります。これに伴い、各国の保健機関は気管支拡大薬の研究開発(R&D)活動を支援しており、市場の展望は明るいと予想されます。

本レポートで扱う主要質問

  • 気管支拡大薬市場の世界市場規模は?
  • 2024~2032年にかけての世界の気管支拡大薬市場の予想成長率は?
  • 世界の気管支拡大薬市場を牽引する主要因は何か?
  • 世界の気管支拡大薬市場に対するCOVID-19の影響は?
  • 気管支拡大薬市場の世界における適応症別内訳は?
  • 世界の気管支拡大薬市場の薬剤タイプ別内訳は?
  • 気管支拡大薬市場の世界における投与経路別内訳は?
  • 気管支拡大薬市場の世界における主要地域は?
  • 世界の気管支拡大薬市場における主要参入企業は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の気管支拡大薬市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:適応症別

  • 喘息
  • 慢性閉塞性肺疾患(COPD)
  • その他

第7章 市場内訳:薬剤タイプ別

  • 交感神経刺激薬
  • 抗コリン薬
  • ホスホジエステラーゼ阻害剤
  • 併用薬

第8章 市場内訳:投与経路別

  • 経口
  • 注射
  • 吸入

第9章 市場内訳:地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • AstraZeneca plc
    • Boehringer Ingelheim International GmbH
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Vectura Group plc
図表

List of Figures

  • Figure 1: Global: Bronchodilators Market: Major Drivers and Challenges
  • Figure 2: Global: Bronchodilators Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Bronchodilators Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Bronchodilators Market: Breakup by Indication (in %), 2023
  • Figure 5: Global: Bronchodilators Market: Breakup by Drug Type (in %), 2023
  • Figure 6: Global: Bronchodilators Market: Breakup by Route of Administration (in %), 2023
  • Figure 7: Global: Bronchodilators Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Bronchodilators (Asthma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Bronchodilators (Asthma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Bronchodilators (Chronic Obstructive Pulmonary Disease - COPD) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Bronchodilators (Chronic Obstructive Pulmonary Disease - COPD) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Bronchodilators (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Bronchodilators (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Bronchodilators (Sympathomimetics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Bronchodilators (Sympathomimetics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Bronchodilators (Anticholinergics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Bronchodilators (Anticholinergics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Bronchodilators (Phosphodiesterase Inhibitor) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Bronchodilators (Phosphodiesterase Inhibitor) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Bronchodilators (Combination Drugs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Bronchodilators (Combination Drugs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Bronchodilators (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Bronchodilators (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Bronchodilators (Injection) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Bronchodilators (Injection) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Bronchodilators (Inhaler) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Bronchodilators (Inhaler) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: North America: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: North America: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: United States: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: United States: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Canada: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Canada: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: Asia-Pacific: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: Asia-Pacific: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: China: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: China: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Japan: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Japan: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: India: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: India: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: South Korea: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: South Korea: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Australia: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Australia: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Indonesia: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Indonesia: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Others: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Others: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Europe: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Europe: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Germany: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Germany: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: France: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: France: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: United Kingdom: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: United Kingdom: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Italy: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Italy: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Spain: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Spain: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Russia: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Russia: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Others: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Others: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Latin America: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Latin America: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Brazil: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Brazil: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Mexico: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Mexico: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Others: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Others: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Middle East and Africa: Bronchodilators Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Middle East and Africa: Bronchodilators Market: Breakup by Country (in %), 2023
  • Figure 76: Middle East and Africa: Bronchodilators Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Global: Bronchodilators Industry: SWOT Analysis
  • Figure 78: Global: Bronchodilators Industry: Value Chain Analysis
  • Figure 79: Global: Bronchodilators Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Bronchodilators Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Bronchodilators Market Forecast: Breakup by Indication (in Million US$), 2024-2032
  • Table 3: Global: Bronchodilators Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 4: Global: Bronchodilators Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 5: Global: Bronchodilators Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Bronchodilators Market: Competitive Structure
  • Table 7: Global: Bronchodilators Market: Key Players
目次
Product Code: SR112024A4184

The global bronchodilators market size reached US$ 37.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 55.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.4% during 2024-2032.

Bronchodilators are medications used to treat patients suffering from long-term conditions of narrow and inflamed airways, such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD). They help relieve associated symptoms by relaxing the muscles around the airways or bronchi, clearing mucus from the lungs, and making breathing easier. They are available in the form of tablets, liquid, nebulizer solutions, and metered-dose and dry powder inhalers. Nowadays, bronchodilators are also utilized to enhance the effect of inhaled corticosteroids, which act as a primary treatment to reduce inflammation and prevent flare-ups in asthma.

Bronchodilators Market Trends:

A significantly rising number of patients with acute respiratory infections due to coronavirus disease (COVID-19) represents one of the key factors influencing the need for bronchodilators across the globe. Apart from this, increasing levels of air pollution, the rising number of smokers, and the growing prevalence of infectious diseases around the world are contributing to the risk of developing lung conditions. This is acting as another growth-inducing factor of the market. In addition, lung function declines gradually with age, which can make breathing slightly difficult. This, along with the increasing geriatric population and a considerable rise in consumer spending capacities, is driving the market. Other factors, such as improving healthcare infrastructure and diagnostic modalities and rising shift towards non-invasive procedures, are also propelling the market growth. Furthermore, several new classes of bronchodilators that can help overcome the limitations of existing products are in the preclinical phase stage. In confluence with this, health agencies of numerous countries are supporting research and development (R&D) activities for bronchodilators, which is anticipated to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bronchodilators market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, drug type and route of administration.

Breakup by Indication:

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Others

Breakup by Drug Type:

Sympathomimetics

Anticholinergics

Phosphodiesterase Inhibitor

Combination Drugs

Breakup by Route of Administration:

Oral

Injection

Inhaler

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc.

Key Questions Answered in This Report

  • 1. How big is the global bronchodilators market?
  • 2. What is the expected growth rate of the global bronchodilators market during 2024-2032?
  • 3. What are the key factors driving the global bronchodilators market?
  • 4. What has been the impact of COVID-19 on the global bronchodilators market?
  • 5. What is the breakup of the global bronchodilators market based on the indication?
  • 6. What is the breakup of the global bronchodilators market based on the drug type?
  • 7. What is the breakup of the global bronchodilators market based on the route of administration?
  • 8. What are the key regions in the global bronchodilators market?
  • 9. Who are the key players/companies in the global bronchodilators market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Bronchodilators Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Indication

  • 6.1 Asthma
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Chronic Obstructive Pulmonary Disease (COPD)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Sympathomimetics
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anticholinergics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Phosphodiesterase Inhibitor
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Combination Drugs
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injection
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Inhaler
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Boehringer Ingelheim International GmbH
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 F. Hoffmann-La Roche Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 GlaxoSmithKline plc
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Sanofi
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Teva Pharmaceutical Industries Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Vectura Group plc
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis